ACX-14

About Applied Cognition

Applied Cognition is pioneering a novel therapeutic approach focused on enhancing the brain's glymphatic waste clearance system to treat neurodegenerative diseases. Its core asset is a proprietary, non-invasive measurement platform that has identified targets and led to a lead small molecule combination candidate, ACX-02, which has shown early biomarker evidence of clearing amyloid and tau. The company is leveraging its platform for ongoing target discovery and drug development, positioning itself at the intersection of neuroscience, physiology, and potential AI-driven insights.

Therapeutic Areas